Ace Laboratories, Inc. Announces Launch of Well-Mints™ Resveratrol + Ribose Hard Candy Lozenges

Friday, March 8, 2019 Drug News
Email Print This Page Comment bookmark
Font : A-A+

Well-Mints™ employ patented drug delivery technology to circumvent resveratrol's bioavailability problem

LOS ANGELES, March 8, 2019 /PRNewswire-PRWeb/ -- Ace Laboratories, Inc. ( announced

today the launch of its first consumer product, Well-Mints™ resveratrol + ribose hard candy lozenges (

Well-Mints™ each contain 100mg of Ver-te™ trans-resveratrol and 485mg of Bioenergy™ ribose in a naturally flavored hard candy base dusted with powdered sugar.

Well-Mints'™ patented technology delivers resveratrol to the body more efficiently than regular tablets or capsules. Well-Mints™ are designed to deliver a more effective dose of resveratrol than oral formulations in a fraction of the time, and without stomach upset.

Dan Wilds, Ace Laboratories' Chairman, remarked "the launch of the company's first consumer product represents the culmination of years of work. Well-Mints™ resveratrol + ribose hard candy lozenges incorporate the refined 'Generally Regarded As Safe' raw materials of its suppliers. Management believes that its novel, patented, lozenge delivery provides potentially meaningful bioavailability of resveratrol for the first time. Resveratrol has been the subject of thousands of studies for years for a wide range of important indications. One of the major problems experienced by past investigators related to what the company expects its proprietary approach resolves: insufficient bioavailability."

Veri-te™ is a registered trade mark of Evolva SA, and Bioenergy™ is a registered trademark of BioEnergy Life Science, Inc.

About Ace Laboratories, Inc. Ace Laboratories is focused on enhancing human health via the application of its proprietary technology to unlock the therapeutic potential of resveratrol. The company's lead pharmaceutical product candidate, AIC-101, is a pharmaceutical formulation of resveratrol delivered in a lozenge. Ace plans to investigate AIC-101 in vascular and inflammatory indications such as Alzheimer's disease and Mild to Moderate Traumatic Brain Injury/Concussion. AIC-101 is a pharmaceutical formulation of resveratrol, a natural polyphenol found in red wine. The resveratrol molecule captured public interest in 2006 after a landmark study showed that it improved the health-span of rodents. In the decades since, a number of human clinical trials have demonstrated that resveratrol has potential to be helpful to patients with vascular and Alzheimer's diseases, and other conditions associated with aging. However, the molecule's large-scale potential has been constrained to date by poor oral bioavailability and dose-limiting gastrointestinal side effects. The Company's management believes that its proprietary technology may effectively address these limitations. Further information about Ace Laboratories, Inc. can be found at:

Forward-Looking Statement This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to," "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions and variations thereof. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Ace Laboratories' actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with funding, product commercialization and commercial operations, unproven preclinical and clinical development activities, regulatory oversight, intellectual property claims, competitive developments, litigation, and the risks, uncertainties and other factors. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the company assumes no obligation to update these forward-looking statements, even if new information becomes available in the future.



SOURCE Ace Laboratories, Inc.

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store